文献速递肿瘤 PET/CT

对比增强FDG PET/CT与64层多排CT在淋巴瘤初始分期及治疗结束时疗效评估中的多中心比较

Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi-Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma.
PubMed 文献 · Clin Nucl Med · 2017-01-01

这项前瞻性多中心研究将181例淋巴瘤患者随机分配至对比增强FDG PET/CT组或64层多排CT组,比较初始分期与治疗结束时疗效评估的准确性。初始分期方面两种方法均与参考标准高度一致(κ=0.96 vs 0.84,P=0.16),但治疗结束时疗效评估仅FDG PET/CT达到优秀一致性(κ=0.91),优于64层多排CT(κ=0.307,P<0.001)。

要点

  • 初始分期FDG PET/CT与64层多排CT均与参考标准高度一致(κ=0.96 vs 0.84,P=0.16)。
  • 治疗结束时疗效评估FDG PET/CT一致性优秀(κ=0.91),优于64层多排CT(κ=0.307,P<0.001)。

核心结论

  • FDG PET/CT与64层多排CT在初始分期中与参考标准一致性满意(κ=0.96 vs 0.84,P=0.16)。
  • 治疗结束时疗效评估FDG PET/CT(κ=0.91)优于64层多排CT(κ=0.307)(P<0.001)。

研究设计与样本

  • 前瞻性研究,比较初始分期与治疗结束时疗效评估。
  • 181例患者随机分配至64层多排CT组或FDG PET/CT组。
  • FDG PET/CT由核医学医师与放射科医师独立阅片并达成事后共识;64层多排CT由另一名独立放射科医师单独判读。
  • 参考标准包括所有临床信息、所有检查及随访。
  • 参与中心的伦理委员会批准研究,所有参与者提供书面知情同意。

主要发现

  • 91例随机至64层多排CT组,90例至FDG PET/CT组;霍奇金淋巴瘤72例,弥漫大B细胞淋巴瘤72例,滤泡性淋巴瘤37例。
  • 初始分期与参考标准一致性:FDG PET/CT κ=0.96,64层多排CT κ=0.84。
  • 治疗结束时疗效评估一致性:FDG PET/CT κ=0.91,64层多排CT κ=0.307。

关键数值与推荐

  • 初始分期FDG PET/CT与参考标准κ=0.96,64层多排CT与参考标准κ=0.84(P=0.16)。
  • 治疗结束时疗效评估FDG PET/CT κ=0.91,64层多排CT κ=0.307(P<0.001)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare staging correctness between contrast-enhanced FDG PET/ceCT and 64-slice multi-detector-row CT (ceCT64) for initial staging and response evaluation at the end of treatment (EOT) in patients with Hodgkin lymphoma, diffuse large B cell lymphoma (DLBCL), and follicular lymphoma. METHODS: This prospective study compared initial staging and response evaluation at EOT. One hundred eighty-one patients were randomly assigned to either ceCT64 or FDG PET/ceCT. A nuclear medicine physician and a radiologist read FDG PET/ceCT scans independently and achieved post hoc consensus, whereas another independent radiologist interpreted ceCT64 separately. The reference standard included all clinical information, all tests, and follow-up. Ethics committees of the participating centers approved the study, and all participants provided written consent. RESULTS: Ninety-one patients were randomized to ceCT64 and 90 to FDG PET/ceCT; 72 had Hodgkin lymphoma, 72 had DLBCL, and 37 had follicular lymphoma. There was excellent correlation between the reference standard and initial staging for both FDG PET/ceCT (κ = 0.96) and ceCT64 (κ = 0.84), although evaluation of the response at EOT was excellent only for FDG PET/ceCT (κ = 0.91). CONCLUSIONS: Our study demonstrated satisfactory agreement between FDG PET/ceCT (κ = 0.96) and ceCT64 (κ = 0.84) in initial staging compared with the reference standard (P = 0.16). Response evaluation at EOT with FDG PET/ceCT (κ = 0.91) was superior compared with ceCT64 (κ = 0.307) (P < 0.001).

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Gómez León N, Delgado-Bolton RC, Del Campo Del Val L, et al. Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi-Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma. Clin Nucl Med. 2017. PMID: 28604477. doi:10.1097/RLU.0000000000001718

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。